SEGMENT INFORMATION- Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Total revenues	$ 776,133	$ 745,740	$ 2,346,688	$ 2,106,602
ALDURAZYME
Disaggregation of Revenue [Line Items]
Total revenues	53,709	71,029	159,123	144,849
Net product revenues
Disaggregation of Revenue [Line Items]
Total revenues	760,812	733,867	2,308,438	2,073,811
Marketed by Company | Products excluding ALDURAZYME
Disaggregation of Revenue [Line Items]
Total revenues	707,103	662,838	2,149,315	1,928,962
Marketed by Company | Products excluding ALDURAZYME | United States
Disaggregation of Revenue [Line Items]
Total revenues	274,114	235,515	788,361	655,963
Marketed by Company | Products excluding ALDURAZYME | Europe
Disaggregation of Revenue [Line Items]
Total revenues	195,184	191,017	667,900	607,755
Marketed by Company | Products excluding ALDURAZYME | Latin America
Disaggregation of Revenue [Line Items]
Total revenues	97,618	111,908	284,018	274,920
Marketed by Company | Products excluding ALDURAZYME | Rest of world
Disaggregation of Revenue [Line Items]
Total revenues	140,187	124,398	409,036	390,324
Marketed by Sanofi | ALDURAZYME
Disaggregation of Revenue [Line Items]
Total revenues	$ 53,709	$ 71,029	$ 159,123	$ 144,849